IP Library Granted Patent US 9,994,607
Granted Patent B2
US 9,994,607 · App. 15/586,634 · Granted Jun 12, 2018

Compounds

Inventors: Jerry Adams (Collegeville, PA); Yiqian Lian (Collegeville, PA)
Assignee: GlaxoSmithKline Intellectual Property Development Limited
C07H21/04A61K31/7084A61K39/39C07F9/65746C07H21/02A61K2039/55511
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,994,607
App. No.
15/586,634
Granted
Jun 12, 2018
Kind
B2
Abstract

A compound of Formula (I) wherein Y 1 , Y 2 , X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 8 , and R 9 are as defined herein; and pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

Claims (36)

1. A compound of Formula (VI):

wherein:

X 51 is O;

X 52 is O;

R 51 is OH and R 52 is NH 2 or R 51 is NH 2 and R 52 is H;

R 53 is OH and R 54 is NH 2 or R 53 is NH 2 and R 54 is H;

R 55 is selected from: F, OH, and OC(O)R 47 ;

R 56 is F;

R 58 and R 59 are independently selected from: H, CH 2 OC(O)R 57 , CH 2 OCO 2 R 57 , CH 2 CH 2 SC(O)R 57 , and CH 2 CH 2 SSCH 2 R 57 ;

where R 57 is selected from: aryl, heteroaryl, heterocycloalkyl, cycloalkyl, C 1-20 alkyl and C 1-20 alkyl substituted with one to 5 substituents independently selected from: aryl, cycloalkyl, hydroxy and F;

provided that at least one of R 58 and R 59 is not H,

or a pharmaceutically acceptable salts thereof.

2. A compound of claim 1 , or a pharmaceutically acceptable salt thereof,

wherein:

R 55 is selected from: F and OH.

3. A compound of claim 2 , or a pharmaceutically acceptable salt thereof,

wherein:

R 55 is OH.

4. A compound of claim 1 selected from:

or a pharmaceutically acceptable salt thereof.

5. A compound of claim 4 which is:

or a pharmaceutically acceptable salt thereof.

6. A compound of claim 4 which is:

or a pharmaceutically acceptable salt thereof.

7. A compound of claim 4 which is:

or a pharmaceutically acceptable salt thereof.

8. A compound of claim 4 which is:

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more of pharmaceutically acceptable excipients.

10. A method of treating a disease state selected from: inflammation, allergic diseases, autoimmune diseases, human immunodeficiency virus (HIV), infectious diseases, cancer, and pre-cancerous syndromes, in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound 1, or a pharmaceutically acceptable salt thereof.

11. The method of claim 10 wherein the mammal is a human.

12. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and an antigen or antigen composition.

13. A vaccine composition comprising an antigen or antigen composition and compound of claim 1 , or a pharmaceutically acceptable salt thereof.

14. An immugenic composition comprising an antigen or antigen composition and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

15. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more immunostimulatory agents.

16. A method of treating a disease selected from: HBV, HCV, influenza, skin warts, multiple sclerosis, and allergic inflammation, in a human in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described in claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2017
From: ADAMS, JERRY LEROY; DUFFY, KEVIN J.; LIAN, YIQIAN
To: GLAXOSMITHKLINE LLC
Reel/Frame 042241/0827 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2017
From: GLAXOSMITHKLINE LLC
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
Reel/Frame 042242/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2017
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 042242/0546 →
Continuity (8)
Continuation 15368921 · Dec 5, 2016
Continuation PCTIB2016057265 · Dec 1, 2016
Provisional Application 62332517 · May 6, 2016
Provisional Application 62327579 · Apr 26, 2016
Provisional Application 62299704 · Feb 25, 2016
Provisional Application 62299253 · Feb 24, 2016
Provisional Application 62262668 · Dec 3, 2015
Related Publication 20170233430A1 · Aug 17, 2017